Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

MiNK Therapeutics, Inc. (INKT)

$11.07 +6.85% NASDAQ: INKT · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: INKT
  • 15 employees
$55.1MMarket cap
-$12.5MNet income
15Employees
INKTNASDAQ
2021IPO

About MiNK Therapeutics, Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$12.5M
Total assets
$14.2M
Market cap
$55.1M
Operating margin
-7013.8%
Net margin
-6931.8%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$180.2K
Operating expenses
$12.8M
Operating income
-$12.6M
Net income
-$12.5M
EPS (basic)
$-2.93
EPS (diluted)
$-2.93

Balance sheet

Total assets
$14.2M
Current assets
$13.8M
Total liabilities
$28.5M
Current liabilities
$13.0M
Shareholders’ equity
-$14.2M

Cash flow

Operating cash flow
-$5.9M
Investing cash flow
-$8.8M
Financing cash flow
$14.7M
Net cash flow
$13.4K

Statements via Polygon.io (SEC filings)

NASDAQ: INKT
$11.07 +6.85%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$6.98 $64.17

52-week range

Market cap
$55.1M
EPS (diluted)
$-2.93
Shares outstanding
5.3M
Open
Day range
Prev close
Volume
IPO date
Oct 15, 2021

MiNK Therapeutics, Inc. (INKT) Stock Price

  • Reported a net loss of $12.5M.
  • Trading 83% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review MiNK Therapeutics, Inc..

Write a review
Newsroom

News about MiNK Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

MiNK Therapeutics, Inc.: frequently asked questions

Is MiNK Therapeutics, Inc. an American company?

MiNK Therapeutics, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is MiNK Therapeutics, Inc. headquartered?

MiNK Therapeutics, Inc. is headquartered in New York, New York, United States.

Is MiNK Therapeutics, Inc. publicly traded?

Yes — MiNK Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol INKT on the NASDAQ.

What does MiNK Therapeutics, Inc. do?

MiNK Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →